Switching from a short-acting to a long-acting methylphenidate preparation: A multicentre, open study in children with ADHD;Umstellung von einem unretardierten auf ein retardiertes methylphenidatpräparat: Eine multizentrische, offene studie an kindern mit ADHS

Zeitschrift fur Kinder- und Jugendpsychiatrie und Psychotherapie

Volumn 34, Issue 4, 2006, Pages 257-265

  Heger, Steffen ^a,j   Trott, Götz Erik ^b   Meusers, Michael ^c   Schulz, Eberhard ^d   Rothenberger, Aribert ^e   Rettig, Klaus ^f   Medori, Rossella ^g   Schreiner, Andreas ^h   Remschmidt, Helmut ⁱ  

^a Praxis für Psychosomatische Medizin und Psychotherapie   (Germany)

^b Gemeinschaftspraxis für Kinder und Jugendpsychiatrie und Psychotherapie   (Germany)

^c Gemeinschaftskrankenhaus Herdecke   (Germany)

^d UNIVERSITY OF FREIBURG   (Germany)

^e UNIVERSITY OF GÖTTINGEN   (Germany)

^f Gesellschaft für Evaluation und Qualitätssicherung in der Medizin   (Germany)

^g Janssen Cilag EMEA Belgium   (Belgium)

^h JANSSEN CILAG GMBH   (Germany)

ⁱ Klinik für Kinder und Jugendpsychiatrie und Psychotherapie   (Germany)

^j NONE   (Germany)

more..

Author keywords

ADHD; Caregiver ratings; Concerta ; Efficacy; Long acting formulas; Methylphenidate; OROS ; Teacher ratings

Indexed keywords

LONG ACTING DRUG; METHYLPHENIDATE; OROS; SHORT ACTING DRUG;

ADOLESCENT; APPETITE; ARTICLE; ATTENTION DEFICIT DISORDER; BODY WEIGHT; CAREGIVER; CHILD; CHILD PSYCHIATRY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFECT; DRUG EFFICACY; DRUG FORMULATION; DRUG METABOLISM; DRUG RELEASE; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; OUTCOME ASSESSMENT; PARENT; PSYCHOLOGICAL RATING SCALE; PSYCHOPHARMACOTHERAPY; RHINOPHARYNGITIS; SCHOOL; SINGLE DRUG DOSE; SLEEP PATTERN; TEACHER; TREATMENT OUTCOME;

ADOLESCENT; ATTENTION; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CENTRAL NERVOUS SYSTEM STIMULANTS; CHILD; DELAYED-ACTION PREPARATIONS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; LONG-TERM CARE; MALE; METHYLPHENIDATE; MOTOR ACTIVITY; PERSONALITY ASSESSMENT; PROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 33746958390     PISSN: 14224917     EISSN: None     Source Type: Journal    
DOI: 10.1024/1422-4917.34.4.257     Document Type: Article

References (18)

1. American Academy of Child and Adolescent Psychiatry. (2002). Practice parameter for the use of stimulant medications in the treatment of children, adolescents, and adults. Journal of the American Academy of Child and Adolescent Psychiatry 41, Supplement 2, 26S-49S.
2. Deutsche Gesellschaft für Kinder- und Jugendpsychiatrie und Psychotherapie. Berufsverband der Ärzte für Kinder- und Jugendpsychiatrie und Psychotherapie in Deutschland. Arbeitsgemeinschaft der leitenden Klinikärzte für Kinder- und Jugendpsychiatrie und Psychotherapie. (2003). Leitlinien zur Diagnostik und Therapie von psychischen Störungen im Säuglings-, Kindes-, und Jugendalter. Deutscher Arzte Verlag, Köln.
3. Faraone, S.V., Spencer, T., Aleardi, M., Pagano, C. & Biederman, J. (2004). Meta-Analysis of the Efficacy of Methylphenidate for Treating Adult Attention-Deficit/Hyperactivity Disorder. Journal of Clinical Psychopharmacology 24, 24-29.
4. Hoare, P., Remschmidt, H., Medori, R., Ettrich, C., Rothenberger, A., Santosh, P., Schmitt, M., Spender, Q., Tamhne, R., Thompson, M., Tinline, C. & Trott, G. E. (2005). 12-month efficacy and safety of OROS® MPH in children and adolescents with attention-deficit/hyperactivity disorder switched from MPH. Eur Child Adolesc Psychiatry, 14, 305-309.
5. Kutcher, S., Aman, M., Brooks, S. J., Buitelaar, J., van Daalen, E., Fegert, J., Findling, R. L., Fisman, S., Greenhill, L. L., Huss, M., Kusumakar, V., Pine, D., Taylor, E. & Tyano, S. (2004). International consensus statement on attention-deficit/hyperactivity disorder (ADHD) and disruptive behaviour disorders (DBDs): clinical implications and treatment practice suggestions. European Neuropsychopharmacology, 14, 11-28.
6. Loney, J. & Milich, R. (1982). Hyperactivity, inattention, and aggression in clinical practice. In: Wolraich, M, Routh, DK, eds. Advances in Development and Behavioral Pediatrics (Vol.3, pp. 113-147). Greenwich, CT: JAI Press.
7. The MTA Cooperative Group. (1999). A 14-Month Randomized Clinical Trial of Treatment Strategies for Attention-Deficit/Hyperactivity Disorder. Archives of General Psychiatry, 56, 1073-1086.
8. Pelham, W. E., Gnagy, E. M., Burrows-Maclean, L., Williams, A., Fabiano, G. A., Morrisey, S. M., Chronis, A. M., Forehand, G. L., Nguyen, C. A., Hoffman, M. T., Lock, T. M., Fielbelkorn, K., Coles, E. K., Panahon, C. J., Steiner, R. L., Meichenbaum, D. L., Onyango, A. N. & Morse, G. D. (2001). Once-a-day Concerta methylphenidate versus three-times-daily methyl-phenidate in laboratory and natural settings. Pediatrics, 107, E105.
9. Remschmidt, H., Hoare, P., Ettrich, C., Rothenberger, A., Santosh, P., Schmidt, M., Spender, Q., Tamhne, R., Thompson, M., Tinline, C., Trott, G. E., Medori, R. (2005). Symptom control in children and adolescents with attention-deficit/hyperactivity disorder on switching from immediate-release MPH to OROS® MPH - Results of a 3-week open-label study. Eur Child Adolesc Psychiatry, 14, 297-304.
10. Stein, M. A. & Greenhill, L. L. (2002). Once-daily Concerta (MPH) for adolescents and adults with ADHD. International Journal of Neuropsychopharmacology, 5, Supplement 1, S162.
11. Swanson, J., Gupta, S., Guinta, D., Flynn, D., Agler, D., Lerner, M., Williams, L., Shoulson, I. & Wigal, S. (1999). Acute tolerance to methylphenidate in the treatment of attention deficit hyperactivity disorder in children. Clinical Pharmacology and Therapeutics, 66, 295-305.
12. Swanson, J. M. (2003). Compliance with Stimulants for Attention-Deficit/Hyperactivity Disorder. CNS Drugs 17, 117-131.
13. Swanson, J. M., Lerner, M. A., Gupta, S., Shoulson, I. & Wigal, S. (2003a). Development of a new once-a-day formulation of methylphenidate for the treatment of ADHD. Archives of General Psychiatry, 60, 204-211.
14. Swanson, J. M., Wigal, S. B., Wigal, T., Sonuga-Barke, E., Greenhill, L. L., Biederman, J., Kollins, S., Nguyen, A. S., DeCory, H. H., Hirshe Dirksen, S. J. & Hatch, S. J.; COMACS Study Group. (2004). A Comparison of Once-Daily Extended-Release Methylphenidate Formulations in Children with Attention/Deficit/Hyperactivity Disorder in the Laboratory School (The Comacs Study). Pediatrics, 113, e206-e216.
15. Taylor, E., Döpfner, M., Sergeant, J., Asherson, P., Banaschewski, T., Buitelaar, J., Coghill, D., Danckaerts, M., Rothenberger, A., Sonuga-Barke, E., Steinhausen, H. C. & Zuddas, A. (2004). European clinical guidelines for hyperkinetic disorder - first upgrade. European Child and Adolescent Psychiatry, 13(1), 17-30.
16. th Annual Meeting of the American Psychiatric Association, Philadelphia, PA, May 18-22.
17. Wilens, T., Pelham, W., Stein, M. A., Conners, C. K., Abikoff, H., Atkins, M., August, G., Greenhill, L., McBurnett, K., Palumbo, D., Swanson, J. & Wolraich, M. (2003). ADHD treatment with once-daily OROS® methylphenidate: interim 12-month results from long-term open-label study. Journal of the American Academy of Child and Adolescent Psychiatry, 42, 424-433.
18. Wolraich, M. L., Greenhill, L. L., Pelham, W., Swanson, J., Wilens, T., Palumbo, D., Atkins, M., McBurnett, K., Bukstein, O. & August, G. (2001). Randomized, controlled trial of OROS methylphenidate once a day in children with attention-deficit/hyperactivity disorder. Pediatrics, 108, 883-892.